October-November 2026 Phase 2/3 Catalysts: BPIQ AI Probability and Stock Move Estimates
We've been working with BPIQ AI to provide more information about upcoming catalysts for investors to consider in their diligence of smid-cap biopharma companies. The table below shows BPIQ AI's predicted probabilities (FN1) that each of 20 October and November 2026 Phase 2 and Phase 3 readouts, across 16 companies, will read out as a clean positive, a clean negative, or with mixed data, along with its predicted stock move for each outcome. Keep in mind that predicting catalyst moves is very complicated, and we are still working with BPIQ AI to improve its predictions.
Based on those numbers, BPIQ AI identified a different, and probably more accurate, set of Suspected Big Mover (SBM) readouts than our traditional SBM analysis (see table). An SBM is a readout where a clean positive or clean negative result could move the stock 20% or more. It also separated up-move and down-move SBM calls and checked options data for each readout. This round, no readout had options clean enough to confirm a Big Mover (BM) upgrade.
BPIQ AI sees very different setups across these readouts. Sixty Degrees Pharmaceuticals (SXTP) is high risk with a very large potential move, Iovance (IOVA) is moderately favorable with a modest expected move, and IDEAYA Biosciences (IDYA) has a high probability of positive data but little incremental move. Six readouts are SBMs in both directions, while several of the most de-risked updates carry the smallest upside.
The key point for investors: a high probability of positive data does not mean a high probability of a positive stock move. The setups with the best odds generally carry the smallest upside, while the largest potential moves come with the highest risk of a sharp decline.
One caution from our own investing experience: the model estimates the clinical outcome first, and the stock reaction does not always follow. In smid-cap biopharma, a Mixed result almost always trades down, and even clean positive data can sell off when expectations are high or the company needs to raise cash. We expect more of these readouts to end in a negative stock move than the Clean- probabilities alone suggest, and we will compare BPIQ AI's estimates against the actual moves as the October and November data come in.
The Full October-November 2026 Table
All 20 readouts, in date order. SBM marks a Suspected Big Mover. Hedge fund (HF) holder counts reflect BPIQ data from the September 18 to 24 analysis.
A note on the smallest companies: SXTP, DWTX and GUTS are valued below $100M. For these, the SBM label is the mechanical output of the rules (a fundamental move of 20% or more with no usable options), and we would not treat it as the same quality of prediction as for a typical $500M to $5B biotech. At these sizes, financing, liquidity and sentiment can overwhelm an otherwise reasonable catalyst estimate.
BM/SBM legend
BM = the low end of the fundamental move range is at least 20% and usable event-specific options independently imply a ≥20% event move.
SBM = the fundamental low-end magnitude is at least 20%, but options either do not confirm it or cannot cleanly isolate the catalyst.
— = the low end of the fundamental move range is below 20%, so the event does not qualify as BM/SBM regardless of implied volatility.
We will compare BPIQ AI's estimates with the actual readouts and stock moves as the October and November data come in. Explore BPIQ's catalyst calendar and review each company's pipeline and financials as part of your diligence.
FN1: The Clean+ probability is a market-outcome probability, not simply the probability that a company calls its press release "positive."
Please note that we have not independently analyzed these readouts manually. No modeling is perfect, and BPIQ AI is still under refinement, so use these estimates as one data point among many in your diligence. This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 10/05/26 EJV, RF
Comments